By continuing, you agree to the Terms of Service.
This website uses cookies to enhance your browsing experience. Learn More.
Essential Cookies
Optional Cookies
Login
Logo for company Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated (CORT)

NASDAQ Currency in USD
$74.33
+$2.71
+3.78%
Last Update: 11 Sept 2025, 20:00
$7.83B
Market Cap
65.20
P/E Ratio (TTM)
Forward Dividend Yield
$35.87 - $117.33
52 Week Range

CORT Stock Price Chart

Explore Corcept Therapeutics Incorporated interactive price chart. Choose custom timeframes to analyze CORT price movements and trends.

CORT Company Profile

Discover essential business fundamentals and corporate details for Corcept Therapeutics Incorporated (CORT) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Biotechnology

IPO Date

14 Apr 2004

Employees

500.00

CEO

Joseph K. Belanoff

Description

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.

CORT Financial Timeline

Browse a chronological timeline of Corcept Therapeutics Incorporated corporate events including earnings releases, dividend announcements, and stock splits.

Upcoming earnings on 4 May 2026

Upcoming earnings on 24 Feb 2026

Upcoming earnings on 29 Oct 2025

EPS estimate is $0.22, while revenue estimate is $223.78M.

Earnings released on 31 Jul 2025

EPS came in at $0.29 surpassing the estimated $0.23 by +26.09%, while revenue for the quarter reached $194.43M , missing expectations by -20.50%.

Earnings released on 5 May 2025

EPS came in at $0.17 matching the estimated $0.17, while revenue for the quarter reached $157.21M , missing expectations by -27.44%.

Earnings released on 26 Feb 2025

EPS came in at $0.26 falling short of the estimated $0.37 by -29.73%, while revenue for the quarter reached $181.89M , missing expectations by -9.11%.

Earnings released on 30 Oct 2024

EPS came in at $0.41 surpassing the estimated $0.28 by +46.43%, while revenue for the quarter reached $182.55M , missing expectations by -7.81%.

Earnings released on 29 Jul 2024

EPS came in at $0.32 surpassing the estimated $0.23 by +39.13%, while revenue for the quarter reached $163.80M , beating expectations by +1.06%.

Earnings released on 1 May 2024

EPS came in at $0.25 surpassing the estimated $0.22 by +13.64%, while revenue for the quarter reached $146.81M , beating expectations by +3.97%.

Earnings released on 15 Feb 2024

EPS came in at $0.28 surpassing the estimated $0.26 by +7.69%, while revenue for the quarter reached $135.41M , beating expectations by +4.72%.

Earnings released on 1 Nov 2023

EPS came in at $0.28 surpassing the estimated $0.22 by +27.27%, while revenue for the quarter reached $123.60M , missing expectations by -3.30%.

Earnings released on 2 Aug 2023

EPS came in at $0.25 surpassing the estimated $0.15 by +66.67%, while revenue for the quarter reached $117.72M , beating expectations by +7.32%.

Earnings released on 3 May 2023

EPS came in at $0.14 falling short of the estimated $0.19 by -26.32%, while revenue for the quarter reached $105.65M , beating expectations by +0.75%.

Earnings released on 28 Feb 2023

EPS came in at $0.14 falling short of the estimated $0.23 by -39.13%, while revenue for the quarter reached $103.06M , missing expectations by -1.93%.

Earnings released on 3 Nov 2022

EPS came in at $0.30 surpassing the estimated $0.23 by +30.43%, while revenue for the quarter reached $101.73M , missing expectations by -5.43%.

Earnings released on 3 Aug 2022

EPS came in at $0.24 matching the estimated $0.24, while revenue for the quarter reached $103.39M , beating expectations by +2.36%.

Earnings released on 5 May 2022

EPS came in at $0.20 falling short of the estimated $0.24 by -16.67%, while revenue for the quarter reached $93.69M , missing expectations by -5.25%.

Earnings released on 15 Feb 2022

EPS came in at $0.26 surpassing the estimated $0.22 by +18.18%, while revenue for the quarter reached $98.82M , missing expectations by -1.74%.

Earnings released on 3 Nov 2021

EPS came in at $0.24 surpassing the estimated $0.20 by +20.00%, while revenue for the quarter reached $96.13M , missing expectations by -1.56%.

Earnings released on 29 Jul 2021

EPS came in at $0.21 surpassing the estimated $0.16 by +31.25%, while revenue for the quarter reached $91.59M , meeting expectations.

Earnings released on 6 May 2021

EPS came in at $0.18 falling short of the estimated $0.21 by -14.29%, while revenue for the quarter reached $79.44M , missing expectations by -10.70%.

Earnings released on 23 Feb 2021

EPS came in at $0.20 surpassing the estimated $0.19 by +5.26%, while revenue for the quarter reached $85.74M , beating expectations by +5.56%.

Earnings released on 3 Nov 2020

EPS came in at $0.17 falling short of the estimated $0.21 by -19.05%, while revenue for the quarter reached $86.33M , missing expectations by -19.05%.

CORT Stock Performance

Access detailed CORT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.

Explore Related Stocks

Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.

Discover More
Command Palette
Search for a command to run